Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.
Initial 24-week data from a study of patients with psoriatic arthritis (PsA) show that treatment with guselkumab improved symptoms and resulted in a higher ACR20 response than placebo in patients who could not tolerate, or did not respond to, treatment with a tumor necrosis factor inhibitor (TNFi).
Filip Van den Bosch, MD, described his strategies for caring for patients with SpA and the possibility of achieving disease inactivity.
Patients’ questions about pro- and anti-inflammatory diets can be challenging to address. Dr. Elena Nikiphorou provided insight into the latest research regarding the role of diet in rheumatic and musculoskeletal diseases.
Vision loss, implications of treatment and more—Sarah Mackie, BMBCh, PhD, MRCP, discussed the latest research on the evaluation and management of giant cell arteritis.
Convex-walking shoes, dietary supplements, advancements in nerve growth factor inhibitors and more—Xavier Chevalier gave an overview and new insights into treatments for osteoarthritis.
Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.
During the 2020 ACR State-of-the-Art Clinical Symposium, Zoltán Szekanecz, MD, PhD, addressed the risks of vascular disease and how to manage them in patients with rheumatic diseases.
Suggestions on how to assess risk and manage bone issues in chronic kidney disease patients are offered…
COVID-19 Global Alliance registry and other data on rheumatic disease patients with COVID-19 were presented…